Clinical Trial Search

Primary: Percentage of Participants Achieving A Clinical Response — 45; 22 Participants

Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg

Primary: Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events — 13; 5 Participants

Primary: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 — 10; 43 Participants — p=<0.0001

Primary: Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 — -60.6963 millimeters of mercury (mmHg)

Primary: Change From Baseline in pVO2 at Week 24 — 1.76; 0.02 mL/kg/min — p=<0.0001

Primary: Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient — -51.05; 19.23 mmHg

Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…

Primary: Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) — 88.9; 90.5; 68.4 percentage of participants

Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506

Primary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic…

Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…

Primary: Recruitment as Assessed by Number of Participants Who Enrolled to the Study — 29; 13 Participants

Primary: Incidence of Adverse Events (AEs) — 10; 7; 11; 4 Participants

Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters

Primary: Right Ventricular Remodeling Index — 0.3747; 0.2817 ratio

Primary: Change in Peak Oxygen Consumption (Peak VO2) — 1.35; 0.08 mL/kg/min

Primary: Change of Daytime Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Pre-treatment and Post-treatment — -8; -3; -4; -3 mm Hg — p=<0.05

Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants

Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44

Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants

Primary: Pleural Pressure (Pes) — 9.3; 4.4 mmHg

Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017

Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min

Primary: Inflammation — -11.47; -37.45; -32.66 percentage of change in crp at week 24

Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio

Primary: Left Ventricular Ejection Fraction — 1.63; 1.69; 4.42 percent of LV diastolic volume

Primary: Patient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantation — 72 Participants

Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73

Primary: Patient Survival at Day-30 Post Transplant and Absence of Severe Primary Heart Graft Dysfunction in the First 24 Hours Post-transplantation — 66 Participants — p=<0.0001